Ildong Pharmaceutical Group’s new drug development company Idience is set to present the clinical research results of the anti-cancer drug candidate “venetoclax” in combination therapy at the American Society of Clinical Oncology (ASCO) on the 29th.
ASCO is the world’s largest cancer conference, taking place in Chicago, Illinois, from the 30th to the 3rd of next month. Idience will present the results of a multinational phase 1b/2a clinical trial related to the combination therapy of venetoclax and irinotecan in poster format for patients with metastatic gastric cancer who have undergone third-line treatment or higher.
Idience is developing a new anti-cancer treatment method for metastatic gastric cancer at the third-line treatment stage or higher by combining the PARP inhibitor venetoclax, which induces cancer cell death by blocking PARP enzymes, with the existing chemotherapy drug irinotecan.
The standard treatment progression-free survival period for metastatic gastric cancer at the third-line treatment stage or higher is only 2 months. The progression-free survival period refers to the duration during which the disease does not worsen after treatment. According to the company, the median progression-free survival period for the combination therapy of venetoclax and irinotecan was reported as 4.2 months, while the median overall survival period was 8 months.
Lee Won-sik, CEO of Idience, noted, “I expect this conference will further highlight the competitiveness of venetoclax and the potential for developing new anti-cancer treatment methods.”